Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/30/2005EP1517915A2 Prodrugs of excitatory amino acids
03/30/2005EP1517914A2 9-alpha-substituted estratrienes as selectively active estrogen
03/30/2005EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
03/30/2005EP1517911A1 Tumour-inhibiting platinum (ii) oxalate complexes
03/30/2005EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
03/30/2005EP1517908A2 Novel benzimidazole derivatives
03/30/2005EP1517907A2 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
03/30/2005EP1517905A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases
03/30/2005EP1517904A2 Mitotic kinesin inhibitors
03/30/2005EP1517899A1 Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
03/30/2005EP1517898A1 Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
03/30/2005EP1517897A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
03/30/2005EP1517896A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
03/30/2005EP1517894A1 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin antagonists and/or serotonin reuptake inhibitors
03/30/2005EP1517893A2 Process for producing levetiracetam
03/30/2005EP1517892A1 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
03/30/2005EP1517891A1 Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof
03/30/2005EP1517890A1 Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
03/30/2005EP1517889A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
03/30/2005EP1517885A2 Aminoacetonitrile derivatives suitable for controlling parasites
03/30/2005EP1517883A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517882A1 Amide linker peroxisome proliferator activated receptor modulators
03/30/2005EP1517881A1 4-(3,3-dihalo-allyloxy)phenoxy alkyl derivatives
03/30/2005EP1517879A1 Aminoalkylphenols, methods of using and making the same
03/30/2005EP1517716A2 Polyacrylates coatings for implantable medical devices
03/30/2005EP1517709A1 Transdermal drug delivery system
03/30/2005EP1517708A1 Combination treatment for depression and anxiety by nk1 and nk3 antagonists
03/30/2005EP1517707A1 Treatment for depression and anxiety with the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent
03/30/2005EP1517706A2 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
03/30/2005EP1517705A1 Dichloroacetate in combination with cardioprotective or hemodynamic drugs
03/30/2005EP1517701A2 Lewis y epitope-containing mucin fusion polypeptide vaccines, compositions and methods of use thereof
03/30/2005EP1517697A1 Acidic insulin preparations with improved stability
03/30/2005EP1517692A1 Method and agent for the prevention, inhibition and treatment of sepsis
03/30/2005EP1517691A1 Use of dopamine receptor agonists for the treatment of cutaneous tumors, warts, and scars
03/30/2005EP1517690A1 Liquid dosage forms of non-enterically coated acid-labile drugs
03/30/2005EP1517689A2 Selective analgesic agents
03/30/2005EP1517688A2 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
03/30/2005EP1517687A1 Medicament for the treatment of the systemic inflammatory response syndrome
03/30/2005EP1517686A2 Use of dantrolene, a ryanodine antagonist, in treating neural injury
03/30/2005EP1517685A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
03/30/2005EP1517683A1 Sustained release tablet containing indapamide
03/30/2005EP1517682A1 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
03/30/2005EP1517681A1 Peritoneal dialysate containing taurine
03/30/2005EP1517680A1 Benzoic acid derivatives as modulators of ppar alpha and gamma
03/30/2005EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1517678A2 Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
03/30/2005EP1517676A1 Oral dosage forms comprising fenofibrate
03/30/2005EP1517675A1 Composition for treatment of inflammatory disorders
03/30/2005EP1517673A1 Nasal composition comprising a mucopolysaccharide and propylene glycol
03/30/2005EP1517672A1 Compositions and methods for amelioration of human female sexual dysfunction
03/30/2005EP1517671A2 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
03/30/2005EP1517667A2 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
03/30/2005EP1517653A1 Methods and devices for treating aneurysms
03/30/2005EP1450770B1 Pharmaceutical composition comprising a 5ht1 receptor agonist
03/30/2005EP1438289B1 Indole derivatives as cox ii inhibitors
03/30/2005EP1436607B1 Ion-sensitive field effect transistor and a method for producing a transistor of this type
03/30/2005EP1436007B1 Compounds for use as surfactants
03/30/2005EP1407047A4 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION
03/30/2005EP1401401B1 Method for high through put screening using a small scale mill or microfluidics
03/30/2005EP1399136B1 Process for the preparation of dispersions
03/30/2005EP1397125B1 Compressible guaifenesin compositions and method for producing them
03/30/2005EP1390037A4 Methods for treating delirium using glucocorticoid receptor-specific antagonists
03/30/2005EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
03/30/2005EP1389909A4 Antimicrobial compounds and methods for their use
03/30/2005EP1365704A4 Radiation cross-linked hydrogels
03/30/2005EP1360184B1 Piperidine derivatives as neurokinin 1 antagonists
03/30/2005EP1345944B1 Process for the isolation and purification of epothilones
03/30/2005EP1337264A4 A nutritional dietary system, formulation, kit and method for use in preparing an individual for a predetermined activity
03/30/2005EP1326616B1 Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder
03/30/2005EP1322350B1 E-ptfe foil impregnated with an encapsulated bioactive substance
03/30/2005EP1307182B1 Pharmaceutical composition for transdermal delivery of befloxatone
03/30/2005EP1290952B1 Compositions for taking dietary fibers
03/30/2005EP1289998B1 New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives
03/30/2005EP1250133B1 Ophthalmic anti-allergy compositions suitable for use with contact lenses
03/30/2005EP1250132B1 Ibuprofen containing active agent preparation
03/30/2005EP1250093B1 Method for preventing fluorescence quenching
03/30/2005EP1250092B1 Method for preventing fluorescence quenching
03/30/2005EP1248597B1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
03/30/2005EP1242089B1 Use of adatanserin for the treatment of acute neurodegenerative disorders
03/30/2005EP1237898B1 N?6 heterocyclic 8-modified adenosine derivatives
03/30/2005EP1237551B1 Pharmaceutical formulations containing zolmitriptan
03/30/2005EP1235831B1 New oxabispidine compounds useful in the treatment of cardiac arrhythmias
03/30/2005EP1227807B1 Irrigation solution and method for inhibition of pain and inflammation
03/30/2005EP1224163B1 Use of carbonylamino derivatives against cns disorders
03/30/2005EP1203088B1 Conditionally controlled, attenuated hiv vaccine
03/30/2005EP1194429B1 Potassium channel openers
03/30/2005EP1194140B1 Pharmaceutical composition containing fenofibrate and preparation method
03/30/2005EP1192127B1 Substituted benzamide inhibitors of rhinovirus 3c protease
03/30/2005EP1191926B1 New omeprazole and (s)-omeprazole formulation
03/30/2005EP1150946B1 Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
03/30/2005EP1147086B1 Compositions for the treatment of skin diseases
03/30/2005EP1105378B1 Quinazoline derivatives
03/30/2005EP1091942B1 Potassium channel blocking agents
03/30/2005EP1087765B1 Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome
03/30/2005EP1076561B1 Combination therapy for the treatment of tumors
03/30/2005EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors
03/30/2005EP1035844B1 The use of polyols in combating yeast infection and polyol preparations for said use
03/30/2005EP0980369B1 Sulfonamides for treatment of endothelin-mediated disorders
03/30/2005EP0928290B1 Oligoribonucleotides and ribonucleases for cleaving rna
03/30/2005EP0900084B1 Use of panaverium bromide for preventing cell proliferation and diseases caused thereby in the liver and digestive tract
1 ... 4738 4739 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 4755 4756 4757 4758 ... 7860